Human evidence · Laboratory findings · Safety gaps · No doses
GHK-Cu is a naturally occurring copper-binding peptide studied mainly in cells, animals and a small amount of topical human research. The cited randomised trial had 13 completers and found no significant objective improvement in redness, wrinkles or overall skin quality, although satisfaction was higher. That trial does not establish injectable GHK-Cu as safe or effective.
GHK-Cu, or Copper Tripeptide-1, is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. The literature includes fibroblast experiments, animal models, mechanistic reviews and limited topical human research. Those evidence types answer different questions and should not be blended into one claim of clinical benefit.
This guide is for educational and research purposes only. The cited literature does not establish injectable GHK-Cu as a safe or effective medicine.
The useful distinction is between topical human evidence and preclinical work:
| Evidence Type | Status |
|---|---|
| Human randomised evidence | One cited topical post-laser trial; 13 people completed it and objective between-group benefits were not significant. |
| Human injectable evidence | No human injectable efficacy or safety trial is cited on this page. |
| Cell and animal evidence | Several studies report biological effects, but they cannot establish a benefit or safety profile in people. |
| Clinical conclusion | The cited studies do not establish an injectable treatment benefit, dose or long-term safety profile. |
GHK binds copper. In a 1988 fibroblast experiment, the copper complex increased collagen synthesis without changing cell number. A separate 2012 study used human lung tissue and fibroblasts to examine gene-expression patterns and collagen remodelling. Both are laboratory findings, not evidence that injecting GHK-Cu treats a condition.
Cell experiments have examined collagen synthesis and gene expression. Animal experiments have examined induced injury or disease models. These studies can identify biological activity, but they do not establish a treatment outcome in people.
The cited randomised human study compared two post-laser topical regimens. Thirteen people completed it. Blinded assessment found no significant between-group difference in redness, wrinkles or overall skin quality at 12 weeks, although participants using the copper-peptide regimen reported higher satisfaction.
The commonly cited 2007 hair-follicle experiment studied AHK-Cu, not GHK-Cu. It used ex vivo human follicles and cultured dermal papilla cells, not a clinical hair-loss trial. It cannot substantiate a human hair-growth claim for GHK-Cu.
| Study / Model | Reported Effect |
|---|---|
| Fibroblast cell culture (Maquart 1988, in vitro) | GHK-Cu stimulated collagen synthesis by fibroblasts. The effect started between 10-12 and 10-11 M and peaked at 10-9 M, and was not explained by any change in cell number. |
| CO2 laser-resurfaced skin (Miller 2006, human, randomised) | Thirteen people completed the study. Blinded evaluators found no significant between-group difference in redness, wrinkles or overall skin quality at 12 weeks. Satisfaction was higher in the copper-peptide group. |
| Human lung tissue and cell culture (Campbell 2012) | GHK reversed a gene-expression signature associated with emphysema-related lung destruction. This is gene-expression work, not a treatment trial. |
| Experimental colitis model (Mao 2025, animal) | GHK-Cu reduced inflammatory markers and colonic tissue damage in an induced-colitis model. Animal work only. |
The cited evidence does not establish a human injectable safety profile. A small topical post-laser trial cannot answer that question. An in vitro keratinocyte study found no cytotoxicity or significant change in selected biomarkers at the tested conditions, but a cell model cannot establish safety in people.
What is GHK-Cu?
GHK-Cu (copper tripeptide-1) is a copper-binding tripeptide. The cited literature includes laboratory, animal and limited topical human research; those evidence types do not establish an injectable clinical benefit.
Is GHK-Cu approved for use in skincare or medicine in Ireland?
The cited human GHK-Cu trial was a small topical post-laser study. It does not establish that injectable GHK-Cu is safe or effective, and cosmetic use is not medicine approval. Topical cosmetic products containing it fall under the EU Cosmetics Regulation, a separate regime.
What has GHK-Cu research actually shown for hair and skin?
The cited 2006 topical trial had 13 completers and found no significant objective difference in redness, wrinkles or overall skin quality, although satisfaction was higher. The commonly cited 2007 hair-follicle experiment studied AHK-Cu, a different peptide, not GHK-Cu.
More evidence-based peptide research guides, free.
Browse the Research GuidesTracking food too? Calorie counter with barcode scanner →
